Press Releases for EXEL

Press Releases
Exelixis Announces August 11 Webcast of Presentation at the Canaccord Adams 29th Annual Global Growth Conference
Exelixis Announces Second Quarter 2009 Financial Results
Exelixis Announces July 30 Webcast of Its Second Quarter 2009 Financial Results Conference Call
Exelixis Announces June 24 Webcast of Presentation at the Piper Jaffray Europe Conference
Exelixis Announces June 9 Webcast of Presentation at the Goldman Sachs Thirtieth Annual Healthcare Conference
Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL765, a Dual Inhibitor of PI3K and mTOR
Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL147, a Selective Inhibitor of PI3K
Exelixis and BMS Report Phase 2 Data to Be Presented at ASCO for XL184 in Patients with Previously Treated Glioblastoma Multiforme
Exelixis Reports Encouraging Phase 1 Data to Be Presented at ASCO for XL228, a Multi-Targeted Inhibitor of Key Cancer Signaling Kinases
Exelixis and Sanofi-aventis Sign Global License Agreement for XL147 & XL765 and Launch Broad Collaboration for Discovery of PI3K Inhibitors
Exelixis Announces May 28 Webcast to Discuss New Collaboration Focused on PI3K Program
Exelixis Announces May 20 Webcast of Presentation at the JMP Securities Eighth Annual Research Conference
Exelixis Announces First Quarter 2009 Financial Results
Exelixis and Boehringer Ingelheim Enter into Collaboration for Development of S1P1 Receptor Agonists in the Field of Autoimmune Diseases
Exelixis Announces May 12 Webcast of Presentation at the Bank of America & Merrill Lynch 2009 Health Care Conference
Exelixis Announces May 7 Webcast of Its First Quarter 2009 Financial Results Conference Call
Seven Abstracts Featuring Exelixis Compounds to Be Presented at 2009 ASCO Annual Meeting
Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company 29th Annual Health Care Conference
Exelixis Announces March 10 Webcast of Presentation at the Barclays Capital Global Healthcare Conference
Exelixis Announces Fourth Quarter and Full Year 2008 Financial Results
Exelixis Announces March 4 Webcast of Its Fourth Quarter and Full Year 2008 Financial Results Conference Call
Exelixis Announces February 10 Webcast of Presentation at the 11th Annual BIO CEO & Investor Conference
Exelixis Announces January 13 Webcast of Presentation at the 27th Annual JPMorgan Healthcare Conference
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs
Reminder: Exelixis Announces December 12 Webcast of Its Fourth Annual R&D Day
Exelixis Reports Positive Phase 1 Data for XL228 at ASH Annual Meeting
Exelixis Reports Phase 1 Data for XL019 at ASH Annual Meeting
Exelixis Announces December 12 Webcast of Its Fourth Annual R&D Day
Exelixis and Bristol-Myers Squibb to Co-Develop XL413, a Selective Cdc7 Inhibitor
Exelixis Announces December 2 Webcast of Presentation at the Piper Jaffray 20th Annual Health Care Conference
Exelixis Announces November 18 Webcast of Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference
Exelixis Research Collaboration With Bristol-Myers Squibb Extended
Exelixis Announces October 30 Webcast of Presentation at the 7th Annual BIO Investor Forum
Exelixis Announces Third Quarter 2008 Financial Results
Exelixis Reports Encouraging Phase 1 Data for XL184 at EORTC-NCI-AACR Symposium
Exelixis Retains Rights to Develop and Commercialize XL184
Exelixis Reports Positive Phase 1 Data for XL281 at EORTC-NCI-AACR Symposium
Exelixis Reports Positive Phase 1 Data for XL228 at EORTC-NCI-AACR Symposium
Exelixis Reports Positive Phase 1 Data for PI3K/mTOR Inhibitor XL765 at EORTC-NCI-AACR Symposium
Exelixis Reports Positive Phase 1 Data for PI3K Inhibitor XL147 at EORTC-NCI-AACR Symposium
Exelixis Announces October 27 Webcast of Its Third Quarter 2008 Financial Results and Business Update Conference Call
Exelixis Will Have 15 Presentations at the 2008 EORTC-NCI-AACR Annual Meeting
Exelixis Submits Diligence Report for Cdc7 Inhibitor to Bristol-Myers Squibb
Exelixis Files IND Application for XL888
Exelixis Announces October 6 Webcast of Presentation at the JMP Securities 3rd Annual Healthcare Focus Conference
CORRECTING and REPLACING Exelixis Announces September 4 Webcast of Presentation at BioCentury's NewsMakers in the Biotech Industry Conference
Exelixis Announces September 4 Webcast of Presentation at BioCentury's NewsMakers in the Biotech Industry Conference
Exelixis Announces September 3 Webcast of Presentation at the Thomas Weisel Partners 2008 Healthcare Conference
Exelixis Announces Second Quarter 2008 Financial Results
Exelixis Announces August 8 Webcast of Presentation at the Bank of America 2008 Specialty Pharmaceuticals Conference
Exelixis Notifies GlaxoSmithKline of Proof-of-Concept for XL184
Exelixis Announces August 5 Webcast of Its Second Quarter 2008 Financial Results and Business Update Conference Call
Exelixis Initiates Phase 3 Trial of XL184 in Medullary Thyroid Cancer
Exelixis Appoints Frances K. Heller As Executive Vice President of Business Development
BeaconEquity.com Issues TraderNotes on Active Stocks: EPEX, LEVP, SANM, CHINA, TASR, TUES, BRCM, EXEL
BeaconEquity.com Issues TraderNotes on Active Stocks: BSRC, DLLR, PGSI, BBND, SGXP, EXEL, OPWV, SCHW
Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
Exelixis Announces June 25 Webcast of Presentation at the Piper Jaffray Europe Conference
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia
Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
Exelixis Receives $150 Million Funding Commitment From Deerfield Management
Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO
Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing - May 27 2008 1:01AM
Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference - Jun 1 2008 9:19PM
Exelixis Announces First Quarter 2008 Financial Results - Jun 1 2008 9:19PM
Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference